The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class. The US regulator is reviewing odronextamab ...
Ordspono (odronextamab) has been cleared by the European Commission to treat adults with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) who have progressed ...
Odronextamab demonstrated a 48.3% objective response rate and 31.7% complete response rate in R/R DLBCL patients post-CAR-T therapy. The median duration of response was 14.8 months, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback